Table 1. . Characteristics of Humira^® formulations and adalimumab biosimilars.

	Humira®	Humira® (citrate free)	Amgevita®/Amjevita®	Imraldi®/Hadlima®	Hyrimoz®	Hulio®	Idacio®	Amsparity®	Yuflyma®	Hukyndra®
EU/US market†	EU/US	EU/US	EU/US‡	EU/US	EU/US	EU	EU	EU	EU/US	EU
Needle size (G) syringe	27	29	29	29	27	29	29	29	29	29
Needle size (G) pen	27	29	27	29	27	29	29	29	29	29
Pre-filled syringe/pen	40 mg/-	20 mg, 40 mg, 80 mg/ 40 mg, 80 mg	20 mg, 40 mg/40 mg	40 mg/ 40 mg	20 mg, 40 mg, 80 mg/ 40 mg, 80 mg	20 mg, 40 mg/ 40 mg	40 mg/ 40 mg	20 mg, 40 mg/40 mg	40 mg, 80 mg/ 40 mg, 80 mg	40 mg, 80 mg/ 40 mg
Citrate	Yes	No	No	No§	No	No	Yes	No	No	No
Latex	Yes	No	Yes	No	No	No	No	No	No	No
Volume (ml) for 40 mg dose	0.8	0.4	0.8	0.4	0.4	0.8	0.8	0.8	0.4	0.4
Availability of 80 mg formulation	No	Yes (since 16 Dec 2021)	No	No	No	No	No	No	Yes	Yes (syringe only)
Shelf life at 25°C, days	14	14	14	31	21	14 (20 mg in 0.4 ml sterile solution), 56 (40 mg in 0.8 ml sterile solution)	28	30 (at 30°C)	31	14

^†As at 4 July 2023.

^‡High-concentration formulation expected to reach US market in 2024.

^§Imraldi^®/Hadlima^® has been citrate-free since the beginning of 2023.